カテゴリー： Market Monitor Global, 世界, 医療/バイオ

グルカゴン様ペプチド 1（GLP-1）ベース治療の世界市場見通し2023年-2029年

◆英語タイトル：Glucagon-like peptide 1 (GLP-1)-based Therapies Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23JU5591）

◆商品コード：MMG23JU5591
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年6月
◆ページ数：71
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品＆医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥494,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥642,200	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥741,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market 調査レポートは次の情報を含め、グローバルにおけるのグルカゴン様ペプチド 1（GLP-1）ベース治療市場規模と予測を収録しています。・世界のグルカゴン様ペプチド 1（GLP-1）ベース治療市場：売上、2018年-2023年、2024年-2029年
・世界のグルカゴン様ペプチド 1（GLP-1）ベース治療市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のグルカゴン様ペプチド 1（GLP-1）ベース治療市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「エクセネイテッド」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

グルカゴン様ペプチド 1（GLP-1）ベース治療のグローバル主要企業は、Novo Nordisk、 AstraZeneca、 Eli Lily、 GSK、 Sanofi、 Bristol-Myers Squibbなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、グルカゴン様ペプチド 1（GLP-1）ベース治療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界のグルカゴン様ペプチド 1（GLP-1）ベース治療市場：タイプ別、2018年-2023年、2024年-2029年
世界のグルカゴン様ペプチド 1（GLP-1）ベース治療市場：タイプ別市場シェア、2022年
・エクセネイテッド、リラグルチド、リキシセナチド、アルビグルチド、デュラグルチド

世界のグルカゴン様ペプチド 1（GLP-1）ベース治療市場：用途別、2018年-2023年、2024年-2029年
世界のグルカゴン様ペプチド 1（GLP-1）ベース治療市場：用途別市場シェア、2022年
・病院、薬局

世界のグルカゴン様ペプチド 1（GLP-1）ベース治療市場：地域・国別、2018年-2023年、2024年-2029年
世界のグルカゴン様ペプチド 1（GLP-1）ベース治療市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業におけるグルカゴン様ペプチド 1（GLP-1）ベース治療のグローバル売上、2018年-2023年
・主要企業におけるグルカゴン様ペプチド 1（GLP-1）ベース治療のグローバル売上シェア、2022年
・主要企業におけるグルカゴン様ペプチド 1（GLP-1）ベース治療のグローバル販売量、2018年-2023年
・主要企業におけるグルカゴン様ペプチド 1（GLP-1）ベース治療のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Novo Nordisk、 AstraZeneca、 Eli Lily、 GSK、 Sanofi、 Bristol-Myers Squibb

*************************************************************

・調査・分析レポートの概要
グルカゴン様ペプチド 1（GLP-1）ベース治療市場の定義
市場セグメント
世界のグルカゴン様ペプチド 1（GLP-1）ベース治療市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のグルカゴン様ペプチド 1（GLP-1）ベース治療市場規模
世界のグルカゴン様ペプチド 1（GLP-1）ベース治療市場規模：2022年 VS 2029年
世界のグルカゴン様ペプチド 1（GLP-1）ベース治療市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのグルカゴン様ペプチド 1（GLP-1）ベース治療の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のグルカゴン様ペプチド 1（GLP-1）ベース治療製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：エクセネイテッド、リラグルチド、リキシセナチド、アルビグルチド、デュラグルチド
グルカゴン様ペプチド 1（GLP-1）ベース治療のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、薬局
グルカゴン様ペプチド 1（GLP-1）ベース治療の用途別グローバル売上・予測

・地域別市場分析
地域別グルカゴン様ペプチド 1（GLP-1）ベース治療市場規模 2022年と2029年
地域別グルカゴン様ペプチド 1（GLP-1）ベース治療売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Novo Nordisk、 AstraZeneca、 Eli Lily、 GSK、 Sanofi、 Bristol-Myers Squibb
...

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
This report aims to provide a comprehensive presentation of the global market for Glucagon-like peptide 1 (GLP-1)-based Therapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glucagon-like peptide 1 (GLP-1)-based Therapies. This report contains market size and forecasts of Glucagon-like peptide 1 (GLP-1)-based Therapies in global, including the following market information:
Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Sales, 2018-2023, 2024-2029, (Units)
Global top five Glucagon-like peptide 1 (GLP-1)-based Therapies companies in 2022 (%)
The global Glucagon-like peptide 1 (GLP-1)-based Therapies market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Exenatied Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Glucagon-like peptide 1 (GLP-1)-based Therapies include Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi and Bristol-Myers Squibb, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Glucagon-like peptide 1 (GLP-1)-based Therapies manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (Units)
Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Segment Percentages, by Type, 2022 (%)
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (Units)
Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Segment Percentages, by Application, 2022 (%)
Hospital
Pharmacy
Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (Units)
Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Glucagon-like peptide 1 (GLP-1)-based Therapies revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Glucagon-like peptide 1 (GLP-1)-based Therapies revenues share in global market, 2022 (%)
Key companies Glucagon-like peptide 1 (GLP-1)-based Therapies sales in global market, 2018-2023 (Estimated), (Units)
Key companies Glucagon-like peptide 1 (GLP-1)-based Therapies sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Outline of Major Chapters:
Chapter 1: Introduces the definition of Glucagon-like peptide 1 (GLP-1)-based Therapies, market overview.
Chapter 2: Global Glucagon-like peptide 1 (GLP-1)-based Therapies market size in revenue and volume.
Chapter 3: Detailed analysis of Glucagon-like peptide 1 (GLP-1)-based Therapies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Glucagon-like peptide 1 (GLP-1)-based Therapies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Glucagon-like peptide 1 (GLP-1)-based Therapies capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Overall Market Size
2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size: 2022 VS 2029
2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales: 2018-2029
3 Company Landscape
3.1 Top Glucagon-like peptide 1 (GLP-1)-based Therapies Players in Global Market
3.2 Top Global Glucagon-like peptide 1 (GLP-1)-based Therapies Companies Ranked by Revenue
3.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Companies
3.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Companies
3.5 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Glucagon-like peptide 1 (GLP-1)-based Therapies Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Product Type
3.8 Tier 1, Tier 2 and Tier 3 Glucagon-like peptide 1 (GLP-1)-based Therapies Players in Global Market
3.8.1 List of Global Tier 1 Glucagon-like peptide 1 (GLP-1)-based Therapies Companies
3.8.2 List of Global Tier 2 and Tier 3 Glucagon-like peptide 1 (GLP-1)-based Therapies Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Markets, 2022 & 2029
4.1.2 Exenatied
4.1.3 Liraglutide
4.1.4 Lixisenatide
4.1.5 Albiglutide
4.1.6 Dulaglutide
4.2 By Type – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue & Forecasts
4.2.1 By Type – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, 2018-2023
4.2.2 By Type – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, 2024-2029
4.2.3 By Type – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share, 2018-2029
4.3 By Type – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales & Forecasts
4.3.1 By Type – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, 2018-2023
4.3.2 By Type – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, 2024-2029
4.3.3 By Type – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share, 2018-2029
4.4 By Type – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Pharmacy
5.2 By Application – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue & Forecasts
5.2.1 By Application – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, 2018-2023
5.2.2 By Application – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, 2024-2029
5.2.3 By Application – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share, 2018-2029
5.3 By Application – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales & Forecasts
5.3.1 By Application – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, 2018-2023
5.3.2 By Application – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, 2024-2029
5.3.3 By Application – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share, 2018-2029
5.4 By Application – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size, 2022 & 2029
6.2 By Region – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue & Forecasts
6.2.1 By Region – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, 2018-2023
6.2.2 By Region – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, 2024-2029
6.2.3 By Region – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share, 2018-2029
6.3 By Region – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales & Forecasts
6.3.1 By Region – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, 2018-2023
6.3.2 By Region – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, 2024-2029
6.3.3 By Region – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, 2018-2029
6.4.2 By Country – North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, 2018-2029
6.4.3 US Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size, 2018-2029
6.4.4 Canada Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size, 2018-2029
6.4.5 Mexico Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, 2018-2029
6.5.2 By Country – Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, 2018-2029
6.5.3 Germany Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size, 2018-2029
6.5.4 France Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size, 2018-2029
6.5.5 U.K. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size, 2018-2029
6.5.6 Italy Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size, 2018-2029
6.5.7 Russia Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size, 2018-2029
6.5.8 Nordic Countries Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size, 2018-2029
6.5.9 Benelux Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, 2018-2029
6.6.2 By Region – Asia Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, 2018-2029
6.6.3 China Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size, 2018-2029
6.6.4 Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size, 2018-2029
6.6.5 South Korea Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size, 2018-2029
6.6.6 Southeast Asia Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size, 2018-2029
6.6.7 India Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, 2018-2029
6.7.2 By Country – South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, 2018-2029
6.7.3 Brazil Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size, 2018-2029
6.7.4 Argentina Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, 2018-2029
6.8.3 Turkey Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size, 2018-2029
6.8.4 Israel Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size, 2018-2029
6.8.5 Saudi Arabia Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size, 2018-2029
6.8.6 UAE Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Novo Nordisk
7.1.1 Novo Nordisk Company Summary
7.1.2 Novo Nordisk Business Overview
7.1.3 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Major Product Offerings
7.1.4 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Revenue in Global (2018-2023)
7.1.5 Novo Nordisk Key News & Latest Developments
7.2 AstraZeneca
7.2.1 AstraZeneca Company Summary
7.2.2 AstraZeneca Business Overview
7.2.3 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Major Product Offerings
7.2.4 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Revenue in Global (2018-2023)
7.2.5 AstraZeneca Key News & Latest Developments
7.3 Eli Lily
7.3.1 Eli Lily Company Summary
7.3.2 Eli Lily Business Overview
7.3.3 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Major Product Offerings
7.3.4 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Revenue in Global (2018-2023)
7.3.5 Eli Lily Key News & Latest Developments
7.4 GSK
7.4.1 GSK Company Summary
7.4.2 GSK Business Overview
7.4.3 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Major Product Offerings
7.4.4 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Revenue in Global (2018-2023)
7.4.5 GSK Key News & Latest Developments
7.5 Sanofi
7.5.1 Sanofi Company Summary
7.5.2 Sanofi Business Overview
7.5.3 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Major Product Offerings
7.5.4 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Revenue in Global (2018-2023)
7.5.5 Sanofi Key News & Latest Developments
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Company Summary
7.6.2 Bristol-Myers Squibb Business Overview
7.6.3 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Major Product Offerings
7.6.4 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Revenue in Global (2018-2023)
7.6.5 Bristol-Myers Squibb Key News & Latest Developments
8 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Production Capacity, Analysis
8.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Production Capacity, 2018-2029
8.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Production Capacity of Key Manufacturers in Global Market
8.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Glucagon-like peptide 1 (GLP-1)-based Therapies Supply Chain Analysis
10.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Value Chain
10.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Upstream Market
10.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Glucagon-like peptide 1 (GLP-1)-based Therapies in Global Market
Table 2. Top Glucagon-like peptide 1 (GLP-1)-based Therapies Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Companies, 2018-2023
Table 5. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Companies, (Units), 2018-2023
Table 6. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Product Type
Table 9. List of Global Tier 1 Glucagon-like peptide 1 (GLP-1)-based Therapies Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Glucagon-like peptide 1 (GLP-1)-based Therapies Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), 2018-2023
Table 15. By Type - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), 2024-2029
Table 16. By Application – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), 2018-2023
Table 20. By Application - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), 2024-2029
Table 21. By Region – Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), 2018-2023
Table 25. By Region - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), 2024-2029
Table 26. By Country - North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, (Units), 2018-2023
Table 29. By Country - North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, (Units), 2024-2029
Table 30. By Country - Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, (Units), 2018-2023
Table 33. By Country - Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, (Units), 2024-2029
Table 34. By Region - Asia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, (Units), 2018-2023
Table 37. By Region - Asia Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, (Units), 2024-2029
Table 38. By Country - South America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, (Units), 2018-2023
Table 41. By Country - South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, (Units), 2024-2029
Table 42. By Country - Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, (Units), 2018-2023
Table 45. By Country - Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, (Units), 2024-2029
Table 46. Novo Nordisk Company Summary
Table 47. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Offerings
Table 48. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. Novo Nordisk Key News & Latest Developments
Table 50. AstraZeneca Company Summary
Table 51. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Offerings
Table 52. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. AstraZeneca Key News & Latest Developments
Table 54. Eli Lily Company Summary
Table 55. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Offerings
Table 56. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. Eli Lily Key News & Latest Developments
Table 58. GSK Company Summary
Table 59. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Offerings
Table 60. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. GSK Key News & Latest Developments
Table 62. Sanofi Company Summary
Table 63. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Offerings
Table 64. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. Sanofi Key News & Latest Developments
Table 66. Bristol-Myers Squibb Company Summary
Table 67. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Offerings
Table 68. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. Bristol-Myers Squibb Key News & Latest Developments
Table 70. Glucagon-like peptide 1 (GLP-1)-based Therapies Production Capacity (Units) of Key Manufacturers in Global Market, 2021-2023 (Units)
Table 71. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Capacity Market Share of Key Manufacturers, 2021-2023
Table 72. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Production by Region, 2018-2023 (Units)
Table 73. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Production by Region, 2024-2029 (Units)
Table 74. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Opportunities & Trends in Global Market
Table 75. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Drivers in Global Market
Table 76. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Restraints in Global Market
Table 77. Glucagon-like peptide 1 (GLP-1)-based Therapies Raw Materials
Table 78. Glucagon-like peptide 1 (GLP-1)-based Therapies Raw Materials Suppliers in Global Market
Table 79. Typical Glucagon-like peptide 1 (GLP-1)-based Therapies Downstream
Table 80. Glucagon-like peptide 1 (GLP-1)-based Therapies Downstream Clients in Global Market
Table 81. Glucagon-like peptide 1 (GLP-1)-based Therapies Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Type in 2022
Figure 2. Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Application in 2022
Figure 3. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, 2018-2029 (US$, Mn)
Figure 7. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales in Global Market: 2018-2029 (Units)
Figure 8. The Top 3 and 5 Players Market Share by Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue in 2022
Figure 9. By Type - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share, 2018-2029
Figure 11. By Type - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share, 2018-2029
Figure 12. By Type - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share, 2018-2029
Figure 15. By Application - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share, 2018-2029
Figure 16. By Application - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share, 2018-2029
Figure 20. By Region - Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share, 2018-2029
Figure 21. By Country - North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share, 2018-2029
Figure 22. By Country - North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share, 2018-2029
Figure 23. US Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share, 2018-2029
Figure 28. Germany Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2029
Figure 29. France Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share, 2018-2029
Figure 37. China Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2029
Figure 41. India Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share, 2018-2029
Figure 43. By Country - South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share, 2018-2029
Figure 44. Brazil Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share, 2018-2029
Figure 48. Turkey Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$, Mn), 2018-2029
Figure 52. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Production Capacity (Units), 2018-2029
Figure 53. The Percentage of Production Glucagon-like peptide 1 (GLP-1)-based Therapies by Region, 2022 VS 2029
Figure 54. Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Value Chain
Figure 55. Marketing Channels

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ グルカゴン様ペプチド 1（GLP-1）ベース治療の世界市場見通し2023年-2029年(Glucagon-like peptide 1 (GLP-1)-based Therapies Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

グルカゴン様ペプチド 1（GLP-1）ベース治療の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp